International Review of Psychiatry
March 31, 2026
Anne Anne Lingford-Hughes
This piece is a personal and evidence-informed perspective on the current status and future direction of addiction psychiatry in the UK, based on my 30 years as a clinical academic addiction psychiatrist. Alcohol and drug addictions are associated with immense burdens to the individual and society, and this is likely to endure. Challenges facing addiction services to overcome include...
Research Square
March 31, 2026
Marcus W. Meinhardt, Ivan Skorodumov, Florian Walter et al.
Abstract Alcohol use disorder is a major global health problem, and current treatments often fail to produce lasting reductions in harmful drinking1,2. Psychedelic-assisted therapies may promote durable behavioural change by enhancing brain plasticity during emotionally meaningful experiences, but progress has been limited by a lack of experimental models that capture these context-dependent...
Psychiatry and Clinical Psychopharmacology
March 30, 2026
Kenji Hashimoto, Feyza Arıcıoğlu, Mesut Çetin
Major depressive disorder remains a leading cause of disability worldwide, and current antidepressants are limited by delayed onset and incomplete response. Building on advances driven by ketamine research, renewed interest has focused on classical serotonergic psychedelics—particularly psilocybin, N,N-dimethyltryptamine (DMT), 5-methoxy-DMT, and lysergic acid diethylamide (LSD)—which, under...
PsyArXiv
March 26, 2026
Broc A. Pagni, Stephen Ross, Sarah E. Mennenga et al.
preprint
Safety and Efficacy of Psilocybin-Assisted Therapy for Alcohol Use Disorder: Open-Label Extension of a Phase II Randomized Controlled Trial
Behavioral Sciences
March 24, 2026
J. Richard Kendrick, Ghonwa Ahmad, Audrey Wood et al.
The use of ketamine for the management of neuropsychiatric conditions outside clinical settings has rapidly expanded, creating a critical need to understand diverse individual experiences. We conducted a qualitative content analysis of posts from the r/TherapeuticKetamine subreddit. From 3302 threads, the 500 highest-engagement threads (12,852 comments) were analyzed by independent coders...
Frontiers in Neuroscience
March 23, 2026
Malkanthi Evans, Andrew Charrette
While the limitations of existing treatment options have spurred investigations into the applicability of psychedelic therapies for chronic and treatment-resistant psychological disorders, there remain significant unresolved issues pertaining to how these treatments should be regulated and the implementation of an ethical framework for their widespread delivery in practice.Research...
Preprints.org
March 17, 2026
Yuki Ueda
preprint
The nature of consciousness, specifically the state of "pure consciousness"—often characterized in contemplative traditions as a state of awareness devoid of intentional content—has transitioned from a topic of purely philosophical inquiry to a rigorous subject of neuroscientific study. This review synthesizes current clinical and neurobiological research to propose that oxytocin (OT), a...
Frontiers in Pharmacology
March 16, 2026
Alessandra Linardi, Ariadiny Lima Caetano, Rodrigo Portes Ureshino
psychiatric disorders, beta-carbolines, trace amine, phosphoproteomics, social hierarchy. Scientific interest in psychedelic substances has re-emerged, offering new perspectives on the treatment of neuropsychiatric and neurological disorders.Historically, psychedelics have been associated with a wide spectrum of positive and negative effects, encompassing ritualistic and spiritual use,...
Pharmacological Reports
March 11, 2026
Benjamin D. Brody, Dora Kanellopoulos
1 citation
Recent retrospective analyses have shown that individuals with comorbid Substance Use Disorders (SUDs) are overrepresented among responders to ketamine for Treatment Resistant Depression (TRD). Ketamine is an effective treatment for depression and also a potential substance of misuse. The authors contrast a mechanistic pathway with a possible expectancy effect to account for these findings, and...
Healthcare
March 3, 2026
Paul Lie, Titus Lie, Madeleine Nguyen et al.
1 citation
This narrative literature review explores the clinical use of Ketamine as part of an untested hypothetical model framework for bridge therapy for acute suicidality. Long-term suicide rates continue to increase in the United States and in many other countries, creating a pressing public health challenge with a variety of treatment considerations. Existing standard-of-care SSRI therapeutics have...
SVOA Medical Research
March 2, 2026
Olumuyiwa A. Bamgbade, Olumide O. Asaolu, Daniel O. Bamgbade et al.
Background: Chronic pain is complicated by comorbid substance misuse. This multifaceted problem increases the risks of polypharmacy, overdose, impaired driving, and avoidable emergency care. Methods: This is an observational study of a convenience sample of twenty adult chronic pain patients who underwent regular monthly intramuscular ketamine for multimodal pain therapy. Ketamine was...
Psychedelic medicine (New Rochelle, N.Y.)
March 1, 2026
Veronica Szpak, Samuel Maddams, Amanda Kim et al.
New treatment options are needed to improve outcomes for patients with both opioid use disorder (OUD) and injection-related infections. Psychedelic-assisted therapy (PAT) has been suggested as a potential treatment for substance use disorders (SUD). To address this need, a qualitative study was conducted to understand the attitudes toward PAT from individuals with OUD who have survived...
BMJ Open
March 1, 2026
Christina Mcanulty, Philippe Lavoie, Samuel Cyr et al.
BACKGROUND: Alcohol use disorder and treatment-resistant depression (TRD) often co-occur, presenting a major clinical challenge with limited effective treatments. However, ketamine produces rapid antidepressant effects and has shown promise in reducing alcohol use, and acceptance and commitment therapy (ACT) can be effective for both substance use and mood disorders. This study explores the...
The Nursing clinics of North America
March 1, 2026
Amanda Canada
Posttraumatic Stress Disorder (PTSD) and Alcohol Use Disorder (AUD) often co-occur, worsening outcomes, relapse rates, and treatment response. Ketamine produces rapid and sustained PTSD symptom reduction and reduces AUD relapse. Prazosin effectively treats PTSD-related nightmares and may reduce alcohol consumption in individuals with heightened autonomic reactivity. The dual complementary...